肾病综合征患者可溶性白介素2受体变化及意义

中国临床药理学与治疗学 ›› 1997, Vol. 2 ›› Issue (2): 85-88.

肾病综合征患者可溶性白介素2受体变化及意义

张道友, 叶任高, 李幼姬, 李惠群, 凌衫洪

皖南医学院弋矾山医院, 芜湖 241001

发布日期:2020-12-06
作者简介:张道友, 男, 副教授, 副主任医师, 安徽省肾脏病学会副主任委员, 安徽名高校和卫生厅跨世纪学科带头人第一层次培养对象。叶任高, 男, 教授, 博士生导师, 中华医学会肾赃病学会常务委员, 中华医学会肾脏病学会中西医结合学会主任委员。

Change of soluble Interleukin-2 receptor and its significance in nephrotic syndrome patients

Zhang Daoyou¹, Ye Rengao, Li Youji, Li Huiqun, Lin Shanhong

¹Department of Nephrology, Affiliated Yijishan Hospital, Wannan Medical College, Wuhu 241001;Renal Research Institute, Sun Yat-Sen University of Medical Sciences

Published:2020-12-06

摘要/Abstract

摘要： 目的研究肾病综合征患者可溶性白介素2受体（SIL-2R)变化及临床意义。方法 36例肾病综合征患者及20例徤康志愿者血、尿标本, 用EL IS A法检測其SI L-2R浓度。结果肾病综合征发作期（252 ± 109u/ml, 167 ± 80u/ml, n = 22)血清及尿液SIL-2R浓度明显高于肾病综合征缓解期（120±26u/ml, 101±46u/ml, w = 14)及徤康对照者（113± 110u/ml, 84± 18u/ml, n = 20, P<0. 01);肾病综合征缓解期和健康对照者无明显差别（P> 0. 05)。血清SIL-2R浓度和血肌酐浓度呈正相关（r = 0. 44, P< 0. 01);尿液SIL-2R、浓度和來蛋白是呈正相关（r = 0. 48, P< 0. 01)。结论 SIL-2R浓度升高可作为肾病综合征活动及（或）肾功能恶化的指标。

关键词: 肾病综合征, 可溶性白介素2受体, 血肌酐, 蛋白尿

Abstract: Aim To investigate the clinical significance of SIL-2R concentrations. Methods Serum and urine soluble interleukin-2 receptors (SIL-2R) were determined with the ELISA method in 36 cases of nephrotic syndrome patients and 20 cases of health volunteers. Results The serum and urine SIL-2R concentrations in the nephrotic stage group (252± 109u/ml, 167 ± 80u/ ml, n = 22) exceeded those in non-nephrotic stage group (120 ± 26u/ ml, 101 ± 46u/ml, n = 14, P<0. 01) and those in healthy controls (113 ± 110u/ml, 84 ± 19u/ml, n = 20, P< 0. 01). There were not any differences in serum and urine SIL-2R concentrations between non-nephrotic stage group and healthy controls (P> 0. 05). Serum SIL-2R con-centrations were correlated with serum creatinine (r = 0. 44, P<0. 01), and urine SIL-2R concentrations were correlated with urine protein excretion (r = 0. 48, P< 0. 01). Conclusion Higher concentration of SIL-2R can serve as an indicator of nephrotic syndrome and (or) renal function exacerbation.

Key words: soluble interleukin-2 receptor, nephrotic syndrome, serum creatinine, pro-teinuria

中图分类号:

R692

张道友, 叶任高, 李幼姬, 李惠群, 凌衫洪. 肾病综合征患者可溶性白介素2受体变化及意义[J]. 中国临床药理学与治疗学, 1997, 2(2): 85-88.

Zhang Daoyou, Ye Rengao, Li Youji, Li Huiqun, Lin Shanhong. Change of soluble Interleukin-2 receptor and its significance in nephrotic syndrome patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1997, 2(2): 85-88.

参考文献

1 Glassock RJ, Adler SA, Ward HJ, et al. Primary glomerular diseases. In: Brenner BM, Rector FC. The Kidney. 4th eds. Philadelphia. W. B. Saunders Company, 1991-1182
2 Nassberger L, Sturfelt G, Thysell H. Serum levels of ssolable interleukin-2 receptor are dependent on the kidney function. Am J Nephrol, 1992, 12:401
3 Mandreoli M, Bcltrandi E, Casadei Maldini M, et al. Lymphocyte release of soluble IL-2 receptors in parents with minimal change nephropathy. Clin Nephrol, 1992, 37:177
4 Ohno I, Gomi H, Matsuda H, et al. Soluble IL-2 receptor in patients with primary nephrotic syndrome. Japanese) Nephrol, 1991, 33:483
5 Yorioka N, Hirabayashi A, Kanahara K, et al. Serum soluble interleukin-2 receptor in patients with glomerulonephritis. Am J Nephrol, 1990, 10, 181
6 Maruyama K, Tomizawa S, Shimabucuro N, et al. Effect of supernatants derived from T-lymphocyte culture in minimal change nephrotic syndrome on rat kidney capillaries., Nephron, 1989, 51:73
7 Novick D. Engelmann H, Wallach D, et al. Soluble cytokine receptors are present in normal human urine. J Exp Med, 1989, 170:1409
8 Chilosi Mf Semenzato G, Vinante F, et al. Increased levels of soluble interleukin-2 receptor in non-Hodg kin' vS lymphomas： Relationship with clinical, histological and phenotypic features. Am J Clin Pathol, 1989, 92:186
9 Manoussakis MN, Papadopoulos GK, Drosos AA, et al. A soluble interleukin-2 receptor molecules in the serum of patients with autoimmune disease. Clin Immunol Immunopathol, 1989, 50:321
10 Kloster BE, John PA, Miller LE, et al. Soluble interleukin-2 recepters are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Im-raunopathol, 1987, 45: 440
11 Tsai CYf Wu. TH, Sun KH, et al. Increased excretion of soluble interleukin-2 receptors and free light chain immunoglobulins in the urine of patients with active lupus nephritis. Ann Rheumat Dis, 1992, 51: 168
12 Laut J, Senitzer D, Petrucci R, et al. Soluble interleukin-2 receptor levels in lupus nephritis. Clin Nephrol, 1992, 38:179

[1]	张军，谢艳云，李智，陶立坚. 剪接因子SRp40调控糖皮质激素受体α/β的表达及其对肾病综合征患者糖皮质激素疗效的影响[J]. 中国临床药理学与治疗学, 2017, 22(5): 589-593.
[2]	冯彩娟，李玉红，何锐，丁倩男，茹国美. 麻醉诱导后晶体液或胶体液对体内液体潴留指数的影响[J]. 中国临床药理学与治疗学, 2016, 21(7): 784-791.
[3]	王艳, 吕莉. 人源型抗C5单克隆抗体Eculizumab的应用[J]. 中国临床药理学与治疗学, 2015, 20(4): 455-459.
[4]	彭健韫, 徐伟海, 张小如, 兰乐健, 桂志红, 项美娟. 小剂量他克莫司联合激素治疗难治性肾病综合征[J]. 中国临床药理学与治疗学, 2014, 19(2): 196-199.
[5]	杨沿浪, 邹和群, 张道友, 汪裕伟, 李芳霞, 高超清, 徐海红, 陈小妹. 贝那普利、螺内酯联用对阿霉素肾病大鼠肾小管保护作用的研究[J]. 中国临床药理学与治疗学, 2012, 17(4): 381-386.
[6]	黄云剑, 王梓华, 张静波, 陈枫, 赵景宏. 吗替麦考酚酯治疗难治性肾病综合征的疗效观察[J]. 中国临床药理学与治疗学, 2009, 14(2): 186-190.
[7]	张道友, 杨沿浪, 杨利才, 徐海红, 汪裕伟. 血管紧张素Ⅱ阻断剂治疗慢性肾小球肾炎时TNF-α和蛋白尿的相关性研究[J]. 中国临床药理学与治疗学, 2008, 13(3): 332-335.
[8]	高绪霞, 张道友, 宋建国, 章辉. 普伐他汀提升肾病综合征合并高凝状态大鼠抗凝血酶Ⅲ水平[J]. 中国临床药理学与治疗学, 2006, 11(7): 801-805.
[9]	吴冀宁, 刘必成. 血管紧张素受体阻滞剂治疗慢性进展性肾病的研究进展[J]. 中国临床药理学与治疗学, 2004, 9(11): 1201-1204.
[10]	胡国华. 雷公藤多苷片对小儿肾性蛋白尿的影响[J]. 中国临床药理学与治疗学, 2003, 8(3): 336-338.
[11]	刘宏, 余济荣, 刘必成, 王艳丽, 尹莲芳, 张晓良. 伊贝沙坦对慢性肾小球肾炎患者血压和尿蛋白排泄的影响[J]. 中国临床药理学与治疗学, 2003, 8(1): 95-97.